 | • レポートコード：QFJ1-4159 • 出版社/出版日：QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、108ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の本調査レポートでは、中枢神経系疾患治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（抗うつ薬、抗不安薬、抗躁病、その他）、用途別市場規模（病院薬局、小売薬局、オンライン薬局）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・中枢神経系疾患治療薬の市場動向 ・企業の競争状況、市場シェア ・中枢神経系疾患治療薬の種類別市場規模と予測2016-2027（抗うつ薬、抗不安薬、抗躁病、その他） ・中枢神経系疾患治療薬の用途別市場規模と予測2016-2027（病院薬局、小売薬局、オンライン薬局） ・中枢神経系疾患治療薬の北米市場規模2016-2027（アメリカ、カナダ） ・中枢神経系疾患治療薬の欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・中枢神経系疾患治療薬のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・中枢神経系疾患治療薬の中南米市場規模2016-2027（メキシコ、ブラジル） ・中枢神経系疾患治療薬の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Alkermes、Astrazeneca、Biogen、Bristol Myers Squibb、Lilly、GSK、Merck、Sunovion Pharmaceuticals、Pfizer、Teva、Norvatis） ・結論 |
A drug used to treat neurological diseases that affect the functioning of the brain or spinal cord in the central nervous system
Market Analysis and Insights: Global Drugs for Central Nervous System Diseases Market
The global Drugs for Central Nervous System Diseases market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Drugs for Central Nervous System Diseases market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Drugs for Central Nervous System Diseases market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Drugs for Central Nervous System Diseases market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Drugs for Central Nervous System Diseases market.
Global Drugs for Central Nervous System Diseases Scope and Market Size
Drugs for Central Nervous System Diseases market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Drugs for Central Nervous System Diseases market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
Antidepressants
Anxiolytics
Anti-manic
Other
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Alkermes
Astrazeneca
Biogen
Bristol Myers Squibb
Lilly
GSK
Merck
Sunovion Pharmaceuticals
Pfizer
Teva
Norvatis
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Drugs for Central Nervous System Diseases Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Antidepressants
1.2.3 Anxiolytics
1.2.4 Anti-manic
1.2.5 Other
1.3 Market by Application
1.3.1 Global Drugs for Central Nervous System Diseases Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Drugs for Central Nervous System Diseases Market Perspective (2016-2027)
2.2 Drugs for Central Nervous System Diseases Growth Trends by Regions
2.2.1 Drugs for Central Nervous System Diseases Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Drugs for Central Nervous System Diseases Historic Market Share by Regions (2016-2021)
2.2.3 Drugs for Central Nervous System Diseases Forecasted Market Size by Regions (2022-2027)
2.3 Drugs for Central Nervous System Diseases Industry Dynamic
2.3.1 Drugs for Central Nervous System Diseases Market Trends
2.3.2 Drugs for Central Nervous System Diseases Market Drivers
2.3.3 Drugs for Central Nervous System Diseases Market Challenges
2.3.4 Drugs for Central Nervous System Diseases Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Drugs for Central Nervous System Diseases Players by Revenue
3.1.1 Global Top Drugs for Central Nervous System Diseases Players by Revenue (2016-2021)
3.1.2 Global Drugs for Central Nervous System Diseases Revenue Market Share by Players (2016-2021)
3.2 Global Drugs for Central Nervous System Diseases Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Drugs for Central Nervous System Diseases Revenue
3.4 Global Drugs for Central Nervous System Diseases Market Concentration Ratio
3.4.1 Global Drugs for Central Nervous System Diseases Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Drugs for Central Nervous System Diseases Revenue in 2020
3.5 Drugs for Central Nervous System Diseases Key Players Head office and Area Served
3.6 Key Players Drugs for Central Nervous System Diseases Product Solution and Service
3.7 Date of Enter into Drugs for Central Nervous System Diseases Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Drugs for Central Nervous System Diseases Breakdown Data by Type
4.1 Global Drugs for Central Nervous System Diseases Historic Market Size by Type (2016-2021)
4.2 Global Drugs for Central Nervous System Diseases Forecasted Market Size by Type (2022-2027)
5 Drugs for Central Nervous System Diseases Breakdown Data by Application
5.1 Global Drugs for Central Nervous System Diseases Historic Market Size by Application (2016-2021)
5.2 Global Drugs for Central Nervous System Diseases Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Drugs for Central Nervous System Diseases Market Size (2016-2027)
6.2 North America Drugs for Central Nervous System Diseases Market Size by Type
6.2.1 North America Drugs for Central Nervous System Diseases Market Size by Type (2016-2021)
6.2.2 North America Drugs for Central Nervous System Diseases Market Size by Type (2022-2027)
6.2.3 North America Drugs for Central Nervous System Diseases Market Size by Type (2016-2027)
6.3 North America Drugs for Central Nervous System Diseases Market Size by Application
6.3.1 North America Drugs for Central Nervous System Diseases Market Size by Application (2016-2021)
6.3.2 North America Drugs for Central Nervous System Diseases Market Size by Application (2022-2027)
6.3.3 North America Drugs for Central Nervous System Diseases Market Size by Application (2016-2027)
6.4 North America Drugs for Central Nervous System Diseases Market Size by Country
6.4.1 North America Drugs for Central Nervous System Diseases Market Size by Country (2016-2021)
6.4.2 North America Drugs for Central Nervous System Diseases Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Drugs for Central Nervous System Diseases Market Size (2016-2027)
7.2 Europe Drugs for Central Nervous System Diseases Market Size by Type
7.2.1 Europe Drugs for Central Nervous System Diseases Market Size by Type (2016-2021)
7.2.2 Europe Drugs for Central Nervous System Diseases Market Size by Type (2022-2027)
7.2.3 Europe Drugs for Central Nervous System Diseases Market Size by Type (2016-2027)
7.3 Europe Drugs for Central Nervous System Diseases Market Size by Application
7.3.1 Europe Drugs for Central Nervous System Diseases Market Size by Application (2016-2021)
7.3.2 Europe Drugs for Central Nervous System Diseases Market Size by Application (2022-2027)
7.3.3 Europe Drugs for Central Nervous System Diseases Market Size by Application (2016-2027)
7.4 Europe Drugs for Central Nervous System Diseases Market Size by Country
7.4.1 Europe Drugs for Central Nervous System Diseases Market Size by Country (2016-2021)
7.4.2 Europe Drugs for Central Nervous System Diseases Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Drugs for Central Nervous System Diseases Market Size (2016-2027)
8.2 Asia-Pacific Drugs for Central Nervous System Diseases Market Size by Type
8.2.1 Asia-Pacific Drugs for Central Nervous System Diseases Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Drugs for Central Nervous System Diseases Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Drugs for Central Nervous System Diseases Market Size by Type (2016-2027)
8.3 Asia-Pacific Drugs for Central Nervous System Diseases Market Size by Application
8.3.1 Asia-Pacific Drugs for Central Nervous System Diseases Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Drugs for Central Nervous System Diseases Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Drugs for Central Nervous System Diseases Market Size by Application (2016-2027)
8.4 Asia-Pacific Drugs for Central Nervous System Diseases Market Size by Region
8.4.1 Asia-Pacific Drugs for Central Nervous System Diseases Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Drugs for Central Nervous System Diseases Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Drugs for Central Nervous System Diseases Market Size (2016-2027)
9.2 Latin America Drugs for Central Nervous System Diseases Market Size by Type
9.2.1 Latin America Drugs for Central Nervous System Diseases Market Size by Type (2016-2021)
9.2.2 Latin America Drugs for Central Nervous System Diseases Market Size by Type (2022-2027)
9.2.3 Latin America Drugs for Central Nervous System Diseases Market Size by Type (2016-2027)
9.3 Latin America Drugs for Central Nervous System Diseases Market Size by Application
9.3.1 Latin America Drugs for Central Nervous System Diseases Market Size by Application (2016-2021)
9.3.2 Latin America Drugs for Central Nervous System Diseases Market Size by Application (2022-2027)
9.3.3 Latin America Drugs for Central Nervous System Diseases Market Size by Application (2016-2027)
9.4 Latin America Drugs for Central Nervous System Diseases Market Size by Country
9.4.1 Latin America Drugs for Central Nervous System Diseases Market Size by Country (2016-2021)
9.4.2 Latin America Drugs for Central Nervous System Diseases Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Drugs for Central Nervous System Diseases Market Size (2016-2027)
10.2 Middle East & Africa Drugs for Central Nervous System Diseases Market Size by Type
10.2.1 Middle East & Africa Drugs for Central Nervous System Diseases Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Drugs for Central Nervous System Diseases Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Drugs for Central Nervous System Diseases Market Size by Type (2016-2027)
10.3 Middle East & Africa Drugs for Central Nervous System Diseases Market Size by Application
10.3.1 Middle East & Africa Drugs for Central Nervous System Diseases Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Drugs for Central Nervous System Diseases Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Drugs for Central Nervous System Diseases Market Size by Application (2016-2027)
10.4 Middle East & Africa Drugs for Central Nervous System Diseases Market Size by Country
10.4.1 Middle East & Africa Drugs for Central Nervous System Diseases Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Drugs for Central Nervous System Diseases Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Alkermes
11.1.1 Alkermes Company Details
11.1.2 Alkermes Business Overview
11.1.3 Alkermes Drugs for Central Nervous System Diseases Introduction
11.1.4 Alkermes Revenue in Drugs for Central Nervous System Diseases Business (2016-2021)
11.1.5 Alkermes Recent Development
11.2 Astrazeneca
11.2.1 Astrazeneca Company Details
11.2.2 Astrazeneca Business Overview
11.2.3 Astrazeneca Drugs for Central Nervous System Diseases Introduction
11.2.4 Astrazeneca Revenue in Drugs for Central Nervous System Diseases Business (2016-2021)
11.2.5 Astrazeneca Recent Development
11.3 Biogen
11.3.1 Biogen Company Details
11.3.2 Biogen Business Overview
11.3.3 Biogen Drugs for Central Nervous System Diseases Introduction
11.3.4 Biogen Revenue in Drugs for Central Nervous System Diseases Business (2016-2021)
11.3.5 Biogen Recent Development
11.4 Bristol Myers Squibb
11.4.1 Bristol Myers Squibb Company Details
11.4.2 Bristol Myers Squibb Business Overview
11.4.3 Bristol Myers Squibb Drugs for Central Nervous System Diseases Introduction
11.4.4 Bristol Myers Squibb Revenue in Drugs for Central Nervous System Diseases Business (2016-2021)
11.4.5 Bristol Myers Squibb Recent Development
11.5 Lilly
11.5.1 Lilly Company Details
11.5.2 Lilly Business Overview
11.5.3 Lilly Drugs for Central Nervous System Diseases Introduction
11.5.4 Lilly Revenue in Drugs for Central Nervous System Diseases Business (2016-2021)
11.5.5 Lilly Recent Development
11.6 GSK
11.6.1 GSK Company Details
11.6.2 GSK Business Overview
11.6.3 GSK Drugs for Central Nervous System Diseases Introduction
11.6.4 GSK Revenue in Drugs for Central Nervous System Diseases Business (2016-2021)
11.6.5 GSK Recent Development
11.7 Merck
11.7.1 Merck Company Details
11.7.2 Merck Business Overview
11.7.3 Merck Drugs for Central Nervous System Diseases Introduction
11.7.4 Merck Revenue in Drugs for Central Nervous System Diseases Business (2016-2021)
11.7.5 Merck Recent Development
11.8 Sunovion Pharmaceuticals
11.8.1 Sunovion Pharmaceuticals Company Details
11.8.2 Sunovion Pharmaceuticals Business Overview
11.8.3 Sunovion Pharmaceuticals Drugs for Central Nervous System Diseases Introduction
11.8.4 Sunovion Pharmaceuticals Revenue in Drugs for Central Nervous System Diseases Business (2016-2021)
11.8.5 Sunovion Pharmaceuticals Recent Development
11.9 Pfizer
11.9.1 Pfizer Company Details
11.9.2 Pfizer Business Overview
11.9.3 Pfizer Drugs for Central Nervous System Diseases Introduction
11.9.4 Pfizer Revenue in Drugs for Central Nervous System Diseases Business (2016-2021)
11.9.5 Pfizer Recent Development
11.10 Teva
11.10.1 Teva Company Details
11.10.2 Teva Business Overview
11.10.3 Teva Drugs for Central Nervous System Diseases Introduction
11.10.4 Teva Revenue in Drugs for Central Nervous System Diseases Business (2016-2021)
11.10.5 Teva Recent Development
11.11 Norvatis
11.11.1 Norvatis Company Details
11.11.2 Norvatis Business Overview
11.11.3 Norvatis Drugs for Central Nervous System Diseases Introduction
11.11.4 Norvatis Revenue in Drugs for Central Nervous System Diseases Business (2016-2021)
11.11.5 Norvatis Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Drugs for Central Nervous System Diseases Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Antidepressants
Table 3. Key Players of Anxiolytics
Table 4. Key Players of Anti-manic
Table 5. Key Players of Other
Table 6. Global Drugs for Central Nervous System Diseases Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Drugs for Central Nervous System Diseases Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Drugs for Central Nervous System Diseases Market Size by Regions (2016-2021) & (US$ Million)
Table 9. Global Drugs for Central Nervous System Diseases Market Share by Regions (2016-2021)
Table 10. Global Drugs for Central Nervous System Diseases Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 11. Global Drugs for Central Nervous System Diseases Market Share by Regions (2022-2027)
Table 12. Drugs for Central Nervous System Diseases Market Trends
Table 13. Drugs for Central Nervous System Diseases Market Drivers
Table 14. Drugs for Central Nervous System Diseases Market Challenges
Table 15. Drugs for Central Nervous System Diseases Market Restraints
Table 16. Global Drugs for Central Nervous System Diseases Revenue by Players (2016-2021) & (US$ Million)
Table 17. Global Drugs for Central Nervous System Diseases Market Share by Players (2016-2021)
Table 18. Global Top Drugs for Central Nervous System Diseases Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Drugs for Central Nervous System Diseases as of 2020)
Table 19. Ranking of Global Top Drugs for Central Nervous System Diseases Companies by Revenue (US$ Million) in 2020
Table 20. Global 5 Largest Players Market Share by Drugs for Central Nervous System Diseases Revenue (CR5 and HHI) & (2016-2021)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Drugs for Central Nervous System Diseases Product Solution and Service
Table 23. Date of Enter into Drugs for Central Nervous System Diseases Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Drugs for Central Nervous System Diseases Market Size by Type (2016-2021) (US$ Million)
Table 26. Global Drugs for Central Nervous System Diseases Revenue Market Share by Type (2016-2021)
Table 27. Global Drugs for Central Nervous System Diseases Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 28. Global Drugs for Central Nervous System Diseases Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 29. Global Drugs for Central Nervous System Diseases Market Size Share by Application (2016-2021) & (US$ Million)
Table 30. Global Drugs for Central Nervous System Diseases Revenue Market Share by Application (2016-2021)
Table 31. Global Drugs for Central Nervous System Diseases Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 32. Global Drugs for Central Nervous System Diseases Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 33. North America Drugs for Central Nervous System Diseases Market Size by Type (2016-2021) (US$ Million)
Table 34. North America Drugs for Central Nervous System Diseases Market Size by Type (2022-2027) & (US$ Million)
Table 35. North America Drugs for Central Nervous System Diseases Market Size by Application (2016-2021) (US$ Million)
Table 36. North America Drugs for Central Nervous System Diseases Market Size by Application (2022-2027) & (US$ Million)
Table 37. North America Drugs for Central Nervous System Diseases Market Size by Country (2016-2021) & (US$ Million)
Table 38. North America Drugs for Central Nervous System Diseases Market Size by Country (2022-2027) & (US$ Million)
Table 39. Europe Drugs for Central Nervous System Diseases Market Size by Type (2016-2021) (US$ Million)
Table 40. Europe Drugs for Central Nervous System Diseases Market Size by Type (2022-2027) & (US$ Million)
Table 41. Europe Drugs for Central Nervous System Diseases Market Size by Application (2016-2021) (US$ Million)
Table 42. Europe Drugs for Central Nervous System Diseases Market Size by Application (2022-2027) & (US$ Million)
Table 43. Europe Drugs for Central Nervous System Diseases Market Size by Country (2016-2021) & (US$ Million)
Table 44. Europe Drugs for Central Nervous System Diseases Market Size by Country (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Drugs for Central Nervous System Diseases Market Size by Type (2016-2021) (US$ Million)
Table 46. Asia-Pacific Drugs for Central Nervous System Diseases Market Size by Type (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Drugs for Central Nervous System Diseases Market Size by Application (2016-2021) (US$ Million)
Table 48. Asia-Pacific Drugs for Central Nervous System Diseases Market Size by Application (2022-2027) & (US$ Million)
Table 49. Asia-Pacific Drugs for Central Nervous System Diseases Market Size by Region (2016-2021) & (US$ Million)
Table 50. Asia-Pacific Drugs for Central Nervous System Diseases Market Size by Region (2022-2027) & (US$ Million)
Table 51. Latin America Drugs for Central Nervous System Diseases Market Size by Type (2016-2021) (US$ Million)
Table 52. Latin America Drugs for Central Nervous System Diseases Market Size by Type (2022-2027) & (US$ Million)
Table 53. Latin America Drugs for Central Nervous System Diseases Market Size by Application (2016-2021) (US$ Million)
Table 54. Latin America Drugs for Central Nervous System Diseases Market Size by Application (2022-2027) & (US$ Million)
Table 55. Latin America Drugs for Central Nervous System Diseases Market Size by Country (2016-2021) & (US$ Million)
Table 56. Latin America Drugs for Central Nervous System Diseases Market Size by Country (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Drugs for Central Nervous System Diseases Market Size by Type (2016-2021) (US$ Million)
Table 58. Middle East & Africa Drugs for Central Nervous System Diseases Market Size by Type (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Drugs for Central Nervous System Diseases Market Size by Application (2016-2021) (US$ Million)
Table 60. Middle East & Africa Drugs for Central Nervous System Diseases Market Size by Application (2022-2027) & (US$ Million)
Table 61. Middle East & Africa Drugs for Central Nervous System Diseases Market Size by Country (2016-2021) & (US$ Million)
Table 62. Middle East & Africa Drugs for Central Nervous System Diseases Market Size by Country (2022-2027) & (US$ Million)
Table 63. Alkermes Company Details
Table 64. Alkermes Business Overview
Table 65. Alkermes Drugs for Central Nervous System Diseases Product
Table 66. Alkermes Revenue in Drugs for Central Nervous System Diseases Business (2016-2021) & (US$ Million)
Table 67. Alkermes Recent Development
Table 68. Astrazeneca Company Details
Table 69. Astrazeneca Business Overview
Table 70. Astrazeneca Drugs for Central Nervous System Diseases Product
Table 71. Astrazeneca Revenue in Drugs for Central Nervous System Diseases Business (2016-2021) & (US$ Million)
Table 72. Astrazeneca Recent Development
Table 73. Biogen Company Details
Table 74. Biogen Business Overview
Table 75. Biogen Drugs for Central Nervous System Diseases Product
Table 76. Biogen Revenue in Drugs for Central Nervous System Diseases Business (2016-2021) & (US$ Million)
Table 77. Biogen Recent Development
Table 78. Bristol Myers Squibb Company Details
Table 79. Bristol Myers Squibb Business Overview
Table 80. Bristol Myers Squibb Drugs for Central Nervous System Diseases Product
Table 81. Bristol Myers Squibb Revenue in Drugs for Central Nervous System Diseases Business (2016-2021) & (US$ Million)
Table 82. Bristol Myers Squibb Recent Development
Table 83. Lilly Company Details
Table 84. Lilly Business Overview
Table 85. Lilly Drugs for Central Nervous System Diseases Product
Table 86. Lilly Revenue in Drugs for Central Nervous System Diseases Business (2016-2021) & (US$ Million)
Table 87. Lilly Recent Development
Table 88. GSK Company Details
Table 89. GSK Business Overview
Table 90. GSK Drugs for Central Nervous System Diseases Product
Table 91. GSK Revenue in Drugs for Central Nervous System Diseases Business (2016-2021) & (US$ Million)
Table 92. GSK Recent Development
Table 93. Merck Company Details
Table 94. Merck Business Overview
Table 95. Merck Drugs for Central Nervous System Diseases Product
Table 96. Merck Revenue in Drugs for Central Nervous System Diseases Business (2016-2021) & (US$ Million)
Table 97. Merck Recent Development
Table 98. Sunovion Pharmaceuticals Company Details
Table 99. Sunovion Pharmaceuticals Business Overview
Table 100. Sunovion Pharmaceuticals Revenue in Drugs for Central Nervous System Diseases Business (2016-2021) & (US$ Million)
Table 101. Sunovion Pharmaceuticals Recent Development
Table 102. Pfizer Company Details
Table 103. Pfizer Business Overview
Table 104. Pfizer Drugs for Central Nervous System Diseases Product
Table 105. Pfizer Revenue in Drugs for Central Nervous System Diseases Business (2016-2021) & (US$ Million)
Table 106. Pfizer Recent Development
Table 107. Teva Company Details
Table 108. Teva Business Overview
Table 109. Teva Drugs for Central Nervous System Diseases Product
Table 110. Teva Revenue in Drugs for Central Nervous System Diseases Business (2016-2021) & (US$ Million)
Table 111. Teva Recent Development
Table 112. Norvatis Company Details
Table 113. Norvatis Business Overview
Table 114. Norvatis Drugs for Central Nervous System Diseases Product
Table 115. Norvatis Revenue in Drugs for Central Nervous System Diseases Business (2016-2021) & (US$ Million)
Table 116. Norvatis Recent Development
Table 117. Research Programs/Design for This Report
Table 118. Key Data Information from Secondary Sources
Table 119. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Drugs for Central Nervous System Diseases Market Share by Type: 2020 VS 2027
Figure 2. Antidepressants Features
Figure 3. Anxiolytics Features
Figure 4. Anti-manic Features
Figure 5. Other Features
Figure 6. Global Drugs for Central Nervous System Diseases Market Share by Application: 2020 VS 2027
Figure 7. Hospital Pharmacies Case Studies
Figure 8. Retail Pharmacies Case Studies
Figure 9. Online Pharmacies Case Studies
Figure 10. Drugs for Central Nervous System Diseases Report Years Considered
Figure 11. Global Drugs for Central Nervous System Diseases Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 12. Global Drugs for Central Nervous System Diseases Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 13. Global Drugs for Central Nervous System Diseases Market Share by Regions: 2020 VS 2027
Figure 14. Global Drugs for Central Nervous System Diseases Market Share by Regions (2022-2027)
Figure 15. Global Drugs for Central Nervous System Diseases Market Share by Players in 2020
Figure 16. Global Top Drugs for Central Nervous System Diseases Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Drugs for Central Nervous System Diseases as of 2020
Figure 17. The Top 10 and 5 Players Market Share by Drugs for Central Nervous System Diseases Revenue in 2020
Figure 18. Global Drugs for Central Nervous System Diseases Revenue Market Share by Type (2016-2021)
Figure 19. Global Drugs for Central Nervous System Diseases Revenue Market Share by Type (2022-2027)
Figure 20. North America Drugs for Central Nervous System Diseases Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 21. North America Drugs for Central Nervous System Diseases Market Share by Type (2016-2027)
Figure 22. North America Drugs for Central Nervous System Diseases Market Share by Application (2016-2027)
Figure 23. North America Drugs for Central Nervous System Diseases Market Share by Country (2016-2027)
Figure 24. United States Drugs for Central Nervous System Diseases Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Canada Drugs for Central Nervous System Diseases Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Drugs for Central Nervous System Diseases Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Drugs for Central Nervous System Diseases Market Share by Type (2016-2027)
Figure 28. Europe Drugs for Central Nervous System Diseases Market Share by Application (2016-2027)
Figure 29. Europe Drugs for Central Nervous System Diseases Market Share by Country (2016-2027)
Figure 30. Germany Drugs for Central Nervous System Diseases Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. France Drugs for Central Nervous System Diseases Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. U.K. Drugs for Central Nervous System Diseases Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Italy Drugs for Central Nervous System Diseases Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Russia Drugs for Central Nervous System Diseases Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Nordic Drugs for Central Nervous System Diseases Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Drugs for Central Nervous System Diseases Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Drugs for Central Nervous System Diseases Market Share by Type (2016-2027)
Figure 38. Asia-Pacific Drugs for Central Nervous System Diseases Market Share by Application (2016-2027)
Figure 39. Asia-Pacific Drugs for Central Nervous System Diseases Market Share by Region (2016-2027)
Figure 40. China Drugs for Central Nervous System Diseases Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Japan Drugs for Central Nervous System Diseases Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. South Korea Drugs for Central Nervous System Diseases Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Southeast Asia Drugs for Central Nervous System Diseases Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. India Drugs for Central Nervous System Diseases Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Australia Drugs for Central Nervous System Diseases Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Drugs for Central Nervous System Diseases Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Drugs for Central Nervous System Diseases Market Share by Type (2016-2027)
Figure 48. Latin America Drugs for Central Nervous System Diseases Market Share by Application (2016-2027)
Figure 49. Latin America Drugs for Central Nervous System Diseases Market Share by Country (2016-2027)
Figure 50. Mexico Drugs for Central Nervous System Diseases Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Brazil Drugs for Central Nervous System Diseases Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Drugs for Central Nervous System Diseases Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Drugs for Central Nervous System Diseases Market Share by Type (2016-2027)
Figure 54. Middle East & Africa Drugs for Central Nervous System Diseases Market Share by Application (2016-2027)
Figure 55. Middle East & Africa Drugs for Central Nervous System Diseases Market Share by Country (2016-2027)
Figure 56. Turkey Drugs for Central Nervous System Diseases Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Saudi Arabia Drugs for Central Nervous System Diseases Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. UAE Drugs for Central Nervous System Diseases Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. Alkermes Revenue Growth Rate in Drugs for Central Nervous System Diseases Business (2016-2021)
Figure 60. Astrazeneca Revenue Growth Rate in Drugs for Central Nervous System Diseases Business (2016-2021)
Figure 61. Biogen Revenue Growth Rate in Drugs for Central Nervous System Diseases Business (2016-2021)
Figure 62. Bristol Myers Squibb Revenue Growth Rate in Drugs for Central Nervous System Diseases Business (2016-2021)
Figure 63. Lilly Revenue Growth Rate in Drugs for Central Nervous System Diseases Business (2016-2021)
Figure 64. GSK Revenue Growth Rate in Drugs for Central Nervous System Diseases Business (2016-2021)
Figure 65. Merck Revenue Growth Rate in Drugs for Central Nervous System Diseases Business (2016-2021)
Figure 66. Sunovion Pharmaceuticals Revenue Growth Rate in Drugs for Central Nervous System Diseases Business (2016-2021)
Figure 67. Pfizer Revenue Growth Rate in Drugs for Central Nervous System Diseases Business (2016-2021)
Figure 68. Teva Revenue Growth Rate in Drugs for Central Nervous System Diseases Business (2016-2021)
Figure 69. Norvatis Revenue Growth Rate in Drugs for Central Nervous System Diseases Business (2016-2021)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed
中枢神経系疾患薬品のグローバル市場：規模・現状・予測2019-2025 A drug used to treat neurological diseases that affect the functioning of the brain or spinal cord in the central nervous systemIn 2018, the global Drugs for Central Nervous System Diseases market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of x…- 中枢神経系疾患薬品のグローバル市場：規模・現状・予測2019-2025 A drug used to treat neurological diseases that affect the functioning of the brain or spinal cord in the central nervous systemIn 2018, the global Drugs for Central Nervous System Diseases market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of x…
- 世界の中枢神経系（CNS）覚醒剤市場規模・現状・予測（2021年-2027年） The central nervous system (CNS) is the part of the nervous system consisting of the brain and spinal cord. The increasing prevalence of CNS disorders such as sleep apnea, narcolepsy, and attention-deficit hyperactivity across the world is increasing the sales and consumption of central nervous syst…
- 世界のインスリン非依存型糖尿病治療薬市場規模・現状・予測（2021年-2027年） Diabetes is a metabolic disease, wherein the body is either unable to secret insulin (type 1 diabetes) or is unable to utilize the generated insulin (type 2 diabetes). Market Analysis and Insights: Global Non Insulin Anti diabetes Drugs Market The global Non Insulin Anti diabetes Drugs market size i…
- 世界の中枢神経系（CNS）リンパ腫治療法市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Central Nervous System (CNS) Lymphoma Treatment Market The global Central Nervous System (CNS) Lymphoma Treatment market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. With industry-standard accu…